Translational Research and Plasma Proteomic in Cancer by Santini, A. C. et al.
Translational Research and Plasma Proteomic in Cancer
Annamaria Chiara Santini,1 Giancarlo Giovane,2 Adelaide Auletta,3 Angelina Di Carlo,4
Alfonso Fiorelli,1 Letizia Cito,5 Carlo Astarita,6 Antonio Giordano,6,7 Roberto Alfano,8
Antonia Feola,3,9 and Marina Di Domenico3,6*
1Department of Morphopathology, Thoracic Surgery Unit, Second University of Naples, Naples, Italy
2Department of Experimental Medicine, Section of Hygiene, Occupational Medicine and Forensic Medicine, Second
University of Naples, Naples, Italy
3Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy
4Department of Medico-Surgical Sciences and Biotechnologies, “Sapienza“ University of Rome, Rome, Italy
5Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori ”Fodazione G. Pascale” - IRCCS,
Naples, Italy
6Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University,
Philadelphia, Pennsylvania
7Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
8Department of Anesthesiological, Surgical and Emergency Sciences. Second University of Naples, Naples, Italy
9Department of Biology, University of Naples “Federico II”, Naples, Italy
ABSTRACT
Proteomics is a recentﬁeld of research inmolecular biology that can help in theﬁght against cancer through the search for biomarkers that can
detect this disease in the early stages of its development. Proteomic is a speedily growing technology, also thanks to the development of even
more sensitive and fast mass spectrometry analysis. Although this technique is the most widespread for the discovery of new cancer
biomarkers, it still suffers of a poor sensitivity and insufﬁcient reproducibility, essentially due to the tumor heterogeneity. Common technical
shortcomings include limitations in the sensitivity of detecting low abundant biomarkers and possible systematic biases in the observed data.
Current research attempts are trying to develop high-resolution proteomic instrumentation for high-throughput monitoring of protein
changes that occur in cancer. In this review, we describe the basic features of the proteomic tools which have proven to be useful in cancer
research, showing their advantages and disadvantages. The application of these proteomic tools could provide early biomarkers detection in
various cancer types and could improve the understanding the mechanisms of tumor growth and dissemination. J. Cell. Biochem. 117: 828–
835, 2016. © 2015 Wiley Periodicals, Inc.
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I t is nowwell establish that to increase the cancer patient survival,an early detection of the disease is fundamental. To reach this
objective, researchers are engaged for a long time in the search for
biomarkers that can detect the disease in the early stages of its
development. An hypothetical biomarker should be a protein or a
metabolite with enough speciﬁcity and sensitivity to discriminate
between normal and pathological conditions. The National Institutes
of Health (NIH) Biomarker working group deﬁned a biomarker as “a
characteristic that is objectively measured and evaluated as an
indicator of normal biologic processes, pathogenic processes, or
pharmacologic response to a therapeutic intervention.
Biomarkers are discriminate in these following classes:
 Predictive biomarkers: predict the response to treatment.
 Diagnostic biomarkers, as a guide to identify the presence and the
progression of pathology.
 Prognostic biomarkers: useful during the pharmacological treat-
ment and to improve the quality of life in patients affected.
The choice of biomarker source plays an essential role, the most
widely used source is undoubtedly plasma or serum other sources
could be urine, saliva, spinal ﬂuid, or biopsies. Serum or plasma are
sources of choice because are easily available and contain large
Annachiara Santini and Giancarlo Giovane have contributed equally to the manuscript.
*Correspondence to: Marina Di Domenico, Department of Biochemistry, Biophysics and General Pathology, Second
University of Naples, Naples 80138, Italy. E-mail: marina.didomenico@unina2.it
Manuscript Received: 9 July 2015; Manuscript Accepted: 16 October 2015
Accepted manuscript online in Wiley Online Library (wileyonlinelibrary.com): 19 October 2015
DOI 10.1002/jcb.25413  © 2015 Wiley Periodicals, Inc. 828
PROSPECTS
Journal of Cellular Biochemistry 117:828–835 (2016)
species of proteins and metabolites, however, proteins of clinically
relevance in plasma span over 10 orders of magnitude in abundance,
thusmaking it difﬁcult to determine proteins poorly represented. The
overall protein content in an organism is now named “Proteome,”
this term was coined in 1994 by Mark Wilkins as model of term
genome, since then much has been made thanks to the development
of technologies such as two-dimensional electrophoresis and mass
spectrometry. Proteome analysis is much more complex than that of
the genome because although the genome of a cell is almost
unchangeable, the proteome is continuously remodeling due to post-
translational modiﬁcations occurring on proteins and that can vary
as a function of the cell metabolic conditions. Post-translational
modiﬁcations like phosphorylation, lipidation, glycosylation, meth-
ylation, acetylation, and nitrosylation, which in healthy cells serve
as key regulator for physiological functions can been found altered
in tumor cells, thus making proteins subject to these changes useful
biomarker. Two-dimensional electrophoresis dates back to the 1970s
when O0Farrel described for the ﬁrst time the separation of proteins
by isoelectric point as a ﬁrst dimension, using anfolines, followed by
separation in the second dimension bymolecular weight with the use
of SDS. Successively the separation by isoelectric point was
improved by the use of immobilines. Although this technique is
largely manual, it suffers for a limited reproducibility. Now an
improvement was obtained with the improvement of the difference
gel electrophoresis (2D-DIGE) that consists of labeling proteins by
ﬂuorescent probe prior to electrophoretic separation. The reference
and sample are labeled with two different probe which have different
excitation and emission wavelength, they are then mixed together
and separated in one single gel run. The gel scanning under two
different wavelengths results in two gel images that can be
superimposed by a software thus showing difference for each
protein migration essentially due to post-translational modiﬁcation.
As complement to two-dimensional electrophoresis, mass spec-
trometry analysis can be used. In fact, spots can be excised from the
gel, proteins digested with trypsin and peptides identiﬁed by matrix-
assisted laser desorption/ionization time-of-ﬂight (MALDI-TOF).
To overcome some of the problems of gel proteomics, researchers
have developed several methods. These methods often use the so
called bottom-up approach (or shotgun) for analyzing the proteome;
they require that the proteins are digested topeptide fragments prior to
their separation. Several different electrophoretic and chromato-
graphic options are available; the most common approach consists in
a separation of peptides by 2-dimensional HPLC chromatography,
followed to electrospray mass spectrometry. The ﬁrst dimension is
usually performed on a strong cation exchange (SCX) column that
fractionates the peptides, eluting them with increasing ionic strength
into a reversed-phase (RP) column, directly coupled by a nano-
electrospray device to a MS/MS spectrometer. Differently from the
2-D Gel, this technique can bemade automated, furthermore it is very
good at enhancing fractionation of complex peptide mixtures, is
highly reproducible and easily integratedwithMS and computational
search techniques. Further improvement to HPLC-MS analysis was
made by the observation that although proteolysis generate a large
number of peptides, only a small part of them are really helpful to
identify a protein. These peptides are called proteotypics and can be
used as a suitable identiﬁer of a protein. A proteotypic peptide should
have the following characteristics: (i) should be observed inmore than
50% of all identiﬁcations of the corresponding protein; (ii) should be
unique for each protein in the database; (iii) should not possess
missing cleavage sites; (vi) its sequence should not include amino acid
susceptible to post-translational modiﬁcations [Dittrich et al., 2014].
Thus, to identify a protein at least one or two proteotypic peptides are
adequate, from this evidence the MS technique called single reaction
monitor (SRM) or multiple reaction monitor (MRM) originally
developed for organic molecules, was applied to peptides tanks also
to the technological improvement of mass spectrometry equipments
with increasing mass scanning speed and better sensitivity. In a
typical MRM analysis, peptides obtained from the digestion of
complex matrices like plasma or tissues are separated by HPLC and
only the proteotypic peptides relative to proteins of interest are
searched by mass in the spectrometer, the fragmentation pattern of
those peptides (transition) conﬁrmunambiguously their sequenceand
the most intense fragment can be used for quantization. Using
appropriate instrumentationand software, about 50 transitions can be
monitored per eachHPLC run . However, the search of peptideMS/MS
data against a database, although is themethodof choice, is not able to
detect newor altered proteins since the database is constituted only by
known proteins. In the cancer proteome, very often are present
aberrant proteins synthesized by mutated genes or by different frame
of translation. Therefore, these cancer-related proteins will be missed
searching ina proteindatabases. It hasbeen calculated that about 20%
of transcripts do not correspond to any protein and the translation of
aberrant genes is difﬁcult using only the genomic approach. To
overcome this problem, a combination of proteomic and genomic
technologies is needed. In fact, the advent of high-throughput nucleic
acid sequencing technologies together with the development of the
mass-spectrometry-based proteomics now allows to validate at
protein level the RNA or DNA sequence found in cancer tissues.
However, considering that samples from two patients with the same
cancermay differ from each other, a large amount of data is necessary
for a proteogenomics database construction and consequently
efﬁcient searching software are required [Woo et al., 2014].
THE BIOMARKER CONCEPT
Cancer etiology and development depend on multigenic factors
driven by environmental factors and cellular events. Due to this
complexity, data from protein expression can be considered a
important resource for comprehension of themolecular pathology of
cancer. The identiﬁcation of proteins associated with cancer has
started to enable early diagnosis and possible treatments at an early
stage; this is crucial and strongly correlated with the chance of
survival. The analysis of protein patterns is a crucial step in
developing the suitable combination of tailored therapies for each
individual. The detection of markers is not easy because cancer
proteome is exceptionally complex and is affected by biological
processes taking place in cancer cells, cancer tissue microenviron-
ment, and cancer cell–host interactions. A major problem is to
distinct proteins associate to the disease from proteins that can be
produced by the cellular inﬂammatory state produced by the disease.
Protein proﬁling can also differ substantially between different areas
of the tumor mass. Moreover, several factors like race, age, diet,
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genetic variability, circadian rhythms, feeding, smoking, stress, and
use of drugs can affect the physiological parameters, hence statistical
signiﬁcance is achieved with numerous analyses. Psychological
stress, which promoting relevant changes in neuronal activity and
gene regulations, also can play huge role in cancer development.
Psychological distress, which can begin with cancer diagnosis and
persist during the treatment, is associated with circadian and
endocrine disorder. For this reason, circadian/endocrine factors are
potent modulators of cancer progression. Some authors [Cash et al.,
2015] hypothesized that circadian activity disruption, distress, and
diurnal cortisol rhythms would be associated with biomarkers of
tumor progression in breast cancer. In this study, patients with poor
circadian coordination and distress present high levels of VEGF,
MMP-9, and TGF-beta factors suggesting tumor invasion/immuno-
suppression. For this reason, we can afﬁrm that depression and
cancer commonly co-occur. Cancer patients generally are affected
by depression which increases with the disease severity. On the other
hand, severe depression may be associated to high risk of cancer.
Possible markers must be conﬁrmed with additional genomic or
metabolomic analysis and quite often, even for the same samples, the
results do not correspond. Advances in proteomics have so far
provided a large list of potential protein cancer markers in the
scientiﬁc literature. To date, a small number of them are clinically
approved, for staging, prognosis or selection of therapy; most of
them are single-protein, serum-derived [Polanski and Anderson,
2007] . Those few are still affected by poor sensitivity and speciﬁcity
[Williams et al., 2007], for example, in liver cancer diagnosis, alpha-
fetoprotein (AFP) has been reported a 50% sensitivity, HER2/NEU is
showing 40% sensitivity in predicting breast cancers, and non-
malignant prostatic diseases can increase levels in serum of prostate-
speciﬁc antigen (PSA) that is routinely used to detect prostate cancer.
Due to the multifactorial nature of cancer, it is clear that a
combination of numerous markers is necessary for an accurate
diagnosis and a tailored of therapy. Proteins need further character-
ization both for their structure (potential post-translational
modiﬁcations) and for their amount to develop diagnostic patterns
speciﬁc for each cancer state. Polanski and Anderson built a
database of potential cancer biomarkers reported by many different
cancer studies. They identiﬁed 1,261 proteins that could, if validated,
contribute to panels of markers that may be useful in early diagnosis
of cancers [Polanski and Anderson, 2007]. The authors have also
indicated a subset of 260 high-priority candidates [Polanski and
Anderson, 2007]. Extracellular proteins represent possible candi-
dates for cancer biomarkers as well as proteins involved in apoptosis,
cell cycle, and proliferation. Changes in protein levels do not provide
full information about protein function. The promising ﬁelds of
phosphoproteomics [Rocchetti et al., 2014] and glycoproteomics
[Zhang et al., 2014] are unraveling protein modiﬁcations. Many
proteins experience post-translational modiﬁcations; changes of
phosphorylation degree is a possible marker of a pathological
condition. Phosphorylation of tyrosine residues is the most studied
phosphorylation event; although phosphorylation of serine and
threonine are more frequent [Cito et al., 2015]. Tyrosine phosphor-
ylation is critical for mitogenic and angiogenic signaling regulation
and tyrosine kinases are often overexpressed or mutated in various
human cancers [Karimi et al., 2014], hence they have also become
attractive targets for anticancer drugs. Studies using reverse-phase
arrays have shown that the phosphorylation and activation of the
serine/threonine kinase AKT is a central early step in prostate cancer
and follicular lymphoma (FL) [Yahiaoui et al., 2014]. Reactive
oxygen or nitrogen can also modify the function or action of
proteins, thus, this protein can represent a great target for proteomic
methods. Gel-based methods are very useful in protein modiﬁcation
studies because they highlight PTMs; the isoelectric point of a
phosphorylated protein is, for example, shifted toward a lower pH
and it could be easily separated from a not phosphorylated form in
2-D maps.
Current diagnostic screening requiring the use of protein
markers. Some protein markers that are currently in clinical use
have substantial limitations regarding their utility for screening.
They include the marker CA125 for ovarian cancer, the PSA for
prostate cancer, the carcinoembryonic antigen CEA for colon
cancer, and pancreatic cancer (CA19-9). For other common
cancers, in particular, breast and lung cancer there are, at this
time, no speciﬁc markers demonstrating clinical utility that can be
used for primary screening. Thus, there is the need for biomarkers
with diagnostic sensitivity and speciﬁcity for detecting common
types of cancer. The considerable number of protein in the blood
and the multiplicity of their modiﬁed forms can be used to provide
information on the health of an individual and of most organs of
the body and provides an opportunity to develop a non-invasive
diagnostic for cancer. Thus, the diagnostics ﬁeld forward will
drive the future generation of personalized medicine where the
individual patient will receive the best possible medicine for the
correct disease [Di Domenico et al., 2013].
LIMITATIONS OF CURRENT CANCER SCREENING
The detection of different cancer types depends heavily on imaging
modalities such as computed tomography (CT) scans for lung cancer,
mammograms for breast cancer, and pelvic ultrasounds for ovarian
cancer. The progress of imaging technology, capable of detecting
even small injuries, is accompanied by an increase in false positives,
needing invasive procedures to make a deﬁnitive diagnosis. Many
advances have been made in proteomic technologies to validate
biological indicators or biomarkers for cancer. The improvement of
biomarker panels will lead to prediction of cancer at early stage of
growth and its response to therapy. Through a protein-based
biomarker analysis for each of the most common cancer types, their
screening will be possible on a single platform.
PROTEOMIC SURVEYS IN DIFFERENT SAMPLES
Biopsies and blood are the most widely used samples for cancer
proteomic surveys [Yang et al., 2014], but also animal tissues, cell
cultures [Serkova and Glunde, 2009], urine [Linden et al., 2012],
saliva [Yang et al., 2014], amniotic [Kim et al., 2014], bile [Grunnet
and Mau-Sorensen, 2014], cerebrospinal [Patel et al., 2014],
follicular, and pancreatic ﬂuids have been used. Tissue-based
proteomic studies are very attractive as they correlate protein
biomarkers directly to the disease. But intra- and inter-cell
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heterogeneity of cancer tissues, due to the contamination of the
healthy tissues and other tissues present, increase the uncertainty
degree of proteins quantization. Moreover, representative samples
are not always in accessible sites, and to obtain them in large
numbers from a biopsy, or during surgical removal of a tumor may
be problematic. It would be appropriate to isolate cancer cells from
the stroma, because the necrotic tissue contaminates serum proteins
and blood cells. We need to remind different methods of success
useful for the capture of cancer cells, as the needle aspiration or
scrapped surface.
Other non-enzymatic methods such as calcium starvation and
immunomagnetic separation are also valid methods for isolation of
cancer cells, as well as the laser-capture microdissection (LCM)
which is a highly sophisticated technique requiring a labor-intensive
procedure.
The urine is an ideal biological sample for the detection of cancer
biomarkers, in fact it is easily available in almost all patients, it is
simple to collect and does not require any invasive procedures.
However, there are several difﬁculties in the use of urinary
proteomics such as low protein concentration, high levels of
interfering compounds (particularly salts), and high degree of
variations (both intra-individual and inter-individual variabilities).
Use of amino acids labeled with stable isotope in cell culture
(SILAC) to compare the secreted proteins (secretome) from pancreatic
cancer-derived cells with that from non-neoplastic pancreatic ductal
cells showed the differential expression of 145 proteins, some of
which not previously detected, that have been also validated by
Western blot analysis [Gronborg et al., 2006].
ICAT (isotope-coded afﬁnity tag) approach is a useful tool in the
identiﬁcation of diagnostic biomarkers in several body ﬂuids,
including cerebrospinal, sinovial, and nipple aspirate ﬂuids [Pawlik
et al., 2006]. The cerebrospinal ﬂuid (CSF) shows a similar protein
content as blood plasma, although with a lesser concentration. Chen
et al. [2006] reported, for the ﬁrst time, results of quantitative
proteomic analysis of pancreatic cancer juice obtained with ICAT.
Qualitative and quantitative analyses with ICAT of proteins differ-
entially expressed in nipple aspirate ﬂuid (NAF) samples were able to
differentiate between patients with early-stage breast cancer and
healthywomen [Pawlik et al., 2006]. However, ICAT technique can be
only applied to protein with sulfhydryl group because it involves
cysteine-speciﬁc tagging of intact proteins followed by proteolytic
digestion. The ITRAQ (isobaric tag for relative and absolute
quantization) technique is more useful because it consists of peptide
chemical derivatizated in the amino groups using a set of multiplexed
amine-reactive reagents with isobaric tags. Another difference
between the ICAT and iTRAQ techniques is that peptides coming
from a sample and control labeled with ICAT possesses different
masses in MS1 wile iTRAQ peptides possesses the same mass in MS1
and different masses after MS2 fragmentation [Wiese et al., 2007].
PLASMA PROTEOMICS IN TUMORS
The blood is an excellent source of candidate biomarkers as it collects
proteins released from tumor and can be easily obtained by a non
invasive procedure. In most proteomic studies, it is not actually
blood that is directly analyzed but rather plasma or serum portion of
blood. The type of blood component that is best for protein proﬁling
and peptidome analysis has been debated. Some investigators favor
the use of plasma because they presume that, in serum, the enzymatic
activity occurring during clotting can produce a cleavage of proteins
involved in biologically relevant pathways.
Among the potential biomarkers of human plasma for cancer
(Table I), only some are recognized; in fact, currently proteomics
technology has a limited sensitivity to detect low-abundance cancer
biomarkers against the background of high-abundance plasma
proteins. Low abundant proteins are often involved in the regulatory
processes thus cancer candidates show generally a lower concen-
tration range than general other plasma proteins [Polanski and
Anderson, 2007]. To overcome this problem, a depletion of high
abundant proteins is performed as an essential treatment for serum
and plasma samples; these treatments delete albumin and globulins
that represent more than 60% of plasma proteins [Dittrich et al.,
2014]. Removal of high abundance protein can deplete up to 90 % of
total protein content and reveal hundreds of additional low
abundance proteins. However, high abundance proteins can serve
as carrier proteins and can bind potentially useful biomarkers and
low abundance proteins can be involved in a nonspeciﬁc binding to
the afﬁnity column used. Proteomic analysis with 2-DE can
simultaneously detect changes of multiple proteins in plasma often
detected differentially expressed proteins are common abundant
plasma proteins and their diagnostic value may be limited. Two-
dimensional electrophoresis (2-DE) has been used for the discovery
of circulating auto-antibodies in cancer patients and annexins I and
II were reported as speciﬁc antigens in sera from patients with lung
TABLE I. Some of Cancer Biomarkers Discovered by Proteomics
Cancer types Biomarkers
Ovarian cancer Cancer antigen 125 (CA125) [Nolen and Lokshin,
2013]; b-2 microglobulin [Yang et al.,
2009] apolipoprotein [Podzielinski et al., 2013];
gene-expression in HE4 [Ferraro et al., 2013]
Breast cancer Fibrinogen A fragment [van den Broek et al., 2010];
BAG6, DDX39, ANXA8, COX4 [Calderon-Gonzalez
et al., 2015]; GCDFP-15 [Darb-Esfahani et al.,
2014]; Versican [Du et al., 2013]; AGR2 [Li et al.,
2015c]; ubiquitin ligase [Goka and Lippman, 2015];
ferritin light chain [Jezequel et al., 2012]
Gastric cancer a1-antitrypsin precursor [Hsu et al., 2007];
pepsinogen C [Terasawa et al., 2014]; Cathepsin B
[Ebert et al., 2005]; galectin-1/-3 [Thijssen et al.,
2015]; miR-214 [Zhang et al., 2015b]; angiopoietin-
like protein 2 [Yoshinaga et al., 2015]; MOR1 [Yao
et al., 2015]; circular RNA [Li et al., 2015a]
Liver cancer Galectin-1/-3 [Thijssen et al., 2015]; CHI3L1/MASP2
[Ding et al., 2014]; Sall4, Glypican-3, dickkopf-1
and talin-1 [Chatterjee and Mitra, 2015]
Pancreatic cancer Vinculin [Wang et al., 2012]; PAM4 [Liu et al., 2015];
cystatin [Jiang et al., 2015]; salivary micro RNAs
[Xie et al., 2015]; glicoprotein panel [Nie et al.,
2014]
Colorectal cancer Vimentin [Bukhari et al., 2015];N-cadherin [Yan et al.,
2015b]; GRObeta [Zheng et al., 2015]; GATA5 and
SFRP2 [Zhang et al., 2015c]; kinesin 26B [Wang
et al., 2015b]; microRNA-155 [Lv et al., 2015];
KRAS [Bruera et al., 2015]
Lung cancer Tyrosine kinase-3 [Zhang et al., 2015a]; Annexin A2
[Yang et al., 2015]; osteopontin [Yan et al., 2015a];
SOX4 [Wang et al., 2015a]; GM2-activator protein
[Potprommanee et al., 2015]; IL1A [Li et al., 2015b];
alpha-actinin 4 [Wang et al., 2015c]
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cancer [Brichory et al., 2001]. Humoral immune response against
tumor antigens in cancer patients have been used in a serum-based
assays to monitor the disease progression or in the development of
anticancer vaccines [GuhaThakurta et al., 2015].
The innate variability of serum among individuals makes it
difﬁcult to compare and validate disease indicators using proteomic
techniques based on gel separation and MS identiﬁcation. High-
throughput automated methods like SELDI-TOF have been exten-
sively used to generate characteristic proteomic patterns of disease,
and search for markers in serum and plasma; many types of tumor
have been investigated [Simsek et al., 2013].
PLASMA PROTEOMIC IN PANCREATIC CANCER
Pancreatic juice contains proteins directly secreted from the
pancreatic ducts, hence it could be the best source for biomarker
from pancreas cancer cells. However, to gain samples from
pancreatic juice is not easy; for this reason, the attention of
investigators has shifted on the search of potential biomarkers in
plasma. However, due to the low abundance in plasma of possible
cancer biomarkers, proteomic technologies are constantly improved
to enhance and reﬁne analysis for biomarker quantiﬁcation. Other
problem arising from biomarker detection in pancreas is due to the
false-positive results coming from pancreatitis because this
inﬂammatory condition shares several molecular features with
pancreatic cancer. Examples of candidate biomarkers that have been
identiﬁed such as asporin, CD9, CXC chemokine ligand 7,ﬁbronectin
1, galectin-1, gelsolin, intercellular adhesionmolecule 1, insulin-like
growth factor binding protein 2, metalloproteinase inhibitor 1,
stromal cell derived factor 4, and transforming growth factor beta-
induced protein.
Many of these proteins are involved in various steps in pancreatic
tumor progression including cell proliferation, adhesion, migration,
invasion, metastasis, immune response, and angiogenesis.
These new protein candidates may provide essential information
for the development of protein diagnostics and targeted therapies
[Mirus et al., 2014]. In the near future, the increasing of sensitivity and
reproducibility of proteomic techniques together with transcriptomic
data will enable a more precise identiﬁcation and validation of
speciﬁc biomarkers of pancreatic cancer that will produce a sure
beneﬁt for patients who will beneﬁt from a targeted treatment.
PLASMA PROTEOMIC IN OVARIAN CANCER
Although there are new drug treatments for ovarian cancer, the 70%
ofwomen affected still die. Therefore, it is necessary a diagnosis at an
early stage of the disease, unfortunately, biomarkers discovered to
date, had not good results in clinical trials.
The ﬁrst biomarker studied in the screening of ovarian cancer was
cancer antigen 125 (CA125) [Bast et al., 1981]. It is a serum marker
whose values may, however, be high in many situations both
gynecological and non-gynecological cancer, both in non-neo-
plastic diseases such as chronic liver disease, pancreatitis. So it does
not give sufﬁcient guarantees to be extended as a screening of the
female population. In women with suspected gynecological disease,
HE4 showed a higher speciﬁcity (93% vs. 78%) and similar
sensitivity (79%) to CA125 for distinguishing benign ovarian
cancer. Studies have shown a potential beneﬁt in combining HE4
and CA125 when quantify the potential risk of malignancy in the
evaluation of a pelvic mass [Nolen et al., 2010].
In the 1990, Jacobs et al. deﬁned the risk of malignancy index
(RMI) considering the CA125 level, the menopausal status and the
ultrasound score to determine likelihood of malignancy in the
setting of an adnexal mass. Later, it has been developed the risk of
malignancy algorithm (ROMA) and the OVA1 test [Nolen and
Lokshin, 2013] for the malignancy risk in women with adnexal
masses: the former is based on HE4 and CA125 serum levels and
menopausal status; the latter on biomarkers discovered through
mass spectrometry, such as b-2 microglobulin, transferrin, trans-
thyretin, and apolipoprotein [Nolen and Lokshin, 2013].
PLASMA PROTEOMIC IN LUNG CANCER
Lung cancer is one of the main cause of death in the world and is
often diagnosed in the advanced or late stages. The discovery of
candidate biomarkers in human lung cancer materials holds clinical
potential as well as a signiﬁcant challenge. Many proteomic
approaches have been used to investigate the biomarkers in human
lung cancer materials. Human plasma, serum and tissues are mostly
used for analysis of biomarkers, whereas urine, cell lines, and pleural
effusion samples are used less often [Fiorelli et al., 2015]. The most
common proteomic approaches used for analysis of the lung cancer
proteome are 2-D electrophoresis (2-DE), two-dimensional differ-
ence in-gel electrophoresis (2-D DIGE), and mass spectrometry (MS)
using matrix-assisted laser desorption/ ionization (MALDI) or
electrospray ionization (ESI) as ion sources. Two-dimensional
electrophoresis is a powerful method and is used to identify the
large scale of the proteome, it still has some limitations: the poor
resolution of separation for less abundant proteins; its detection of
proteins with extreme properties (small, large, hydrophobic, and
strong acidic or basic) is limited; and it is time consuming and
expensive.
Recently, many efforts have been made to improve the resolution
of protein separation in proteomic analysis, for example, a
combination of multi-dimensional liquid chromatography (LC)
and very small amounts of a sample, and can analyze the complex
biological mixtures directly. It has been used to analyze the
proteome of lung cancer materials. The immobilizing speciﬁc
monoclonal antibodies or phage-expressed proteins on the chips,
known as protein arrays, allow for quantitation of distinct proteins
from different lung cancer samples.
The test of seropositivity for tumor antigens to determine the
presence of cancer is a humoral response that occurs during the
outset of the tumor and generates an ampliﬁed signal appreciable in
the blood in the form of autoantibodies. Proteomic technologies ﬁt
well for the identiﬁcation of tumor antigens that induce autoanti-
bodies. A protein microarray approach was applied to discover and
validate lung cancer tumor antigens associated with autoantibodies.
Array analysis, which can deﬁne up- and down-regulated
proteins in lung cancer samples with high accuracy, is a promising
approach for additional diagnosis of lung cancer. Two-dimensional
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electrophoresis or mass spectrometry (LC-MS) has been applied to
plasma proteomics in lung cancer [Liotta and Petricoin, 2011].
Validation of cancer biomarkers requires different experimental
approaches due to protein heterogeneities. In fact, chemical
modiﬁcations, cleavages, complex with antibody, and other proteins
makes them hard to be identiﬁed. Plasma biomarkers have been
investigated in an integrative study on lung cancer [Serkova and
Glunde, 2009] in which plasmas from three mouse models of lung
adenocarcinoma have been analyzed in a quantitative proteomic
analysis. The adenocarcinoma models were obtained by a mutation
of epidermal growth factor receptor (EGFR) or Kras, induced by
urethane exposure, and a mouse model of small-cell lung cancer
lacking of Trp53 and Rb.
Data obtained from proteome investigation of lung cancer were
compared with those obtained from other cancer mouse models like
ovarian, pancreatic, colon, prostate and breast in addition to 2
models of inﬂammation [Di Domenico et al., 2011].
In plasmas of mouse models of lung adenocarcinoma were
identiﬁed several proteins regulated by Nkx2–1, a transcription
factor in cells from the peripheral airways, and a known survival
oncogene in lung cancer. Furthermore, in plasma of mice with lung
tumors determined by a mutant of human EGFR was found a
upregulated group of proteins whose concentration decreased
following a treatment with a tyrosine kinase inhibitor. In order to
assess the correspondence between mouse models and human lung
cancer an array of protein identiﬁed as marker in mice lung cancer
were assayed in samples of human plasma. Since in lung cancer,
through the proteomic analysis, antibodies against tumor antigens
have been identiﬁed, results obtained with this method have been
implemented with those obtained by autoantibodies with the
microarray technology. If the results obtained with proteomic
investigations of post-translational modiﬁcations like glycosylation
could be further integrated, a panel of markers with high speciﬁcity
and diagnostic sensitivity for lung cancer could be obtained. The
proteomic technologies for the detection of tumor markers are very
promising, but they are also difﬁcult to transfer to diagnostic
analysis that requires a high number of investigations, to date no
reference standards have been developed. However, in the plasma, in
addition to proteins, there are other molecules and cell populations
that can be used as cancer biomarkers. Very promising are the
microRNAs and circulating tumor cells, but also metabolites,
mutated DNA, or DNA methylated fragments. The metabolome
offers the opportunity for the discovery of new biomarkers due to its
constant changes as a result of the organism state. However, the
difﬁculty lies in identifying what is the concentration range in which
a metabolite may be considered physiological or pathological; to
solve this problem, a large amount of data are required to obtain
statistically signiﬁcant results. Although the proteomic technologies
require high labor intensity with high costs, the results that can
produce fully justify the investment, but little consideration is given
to the use of proteomics in clinical diagnostic. Genomic analysis
often requires the availability of tissue, which is usually obtained
through a biopsy or during surgery, while proteomics, in addition to
the analysis of tissue, is suitable for body ﬂuid samples more easily
available. Therefore, an important advantage of proteomics is the
ability to analyze the plasma of an individual in pre-diagnosis to
detect the disease at an early stage and after treatment to assess
response to therapy. Furthermore, proteomics can be used tomonitor
the patient status during all the treatment steps by means of a simple
blood test. There is still the need for a comparison of the results
produced by proteomic analyses against other diagnostic approaches
based on blood test for assessing the risk of other diseases [Fiorelli
et al., 2014].
CONCLUSIONS
Proteomic technologies still face important technical challenges, as
it is still lacking of standardized methodologies, sensitivity, and
reproducibility. Common technical shortcomings include limitations
in the sensitivity of detecting low abundant biomarkers and possible
systematic biases in the observed data. Current research is focused on
the development of high-resolution proteomic instrumentation for
high-throughput monitoring of protein changes occurring in cancer.
However, it is now clear that proteome analysis alone could not
satisfy all requisites necessary to obtain reproducible and signi-
ﬁcative results, hence in the post-genomic era a new ﬁeld of
investigation is growing: proteogenomic. Proteogenomic, in fact,
can overtake the problem of identifying mutated proteins from
peptides in a in bottom-up proteomics. Of course to reach this result,
a consolidated database containing sequences of mutated protein
obtained from translation of mutated nucleic acids is required.
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